Glucose Health, Inc. Appoints Veteran Financial Executive Edmund “Ned” Burke to Its Board of Directors
Glucose Health (OTC: GLUC) appointed Edmund “Ned” Burke to its Board of Directors effective Oct 27, 2025. Burke is a veteran financial executive with 40+ years at firms including Pioneer Funds and Fidelity, and served as CEO of ALPS Holdings until his June 2019 retirement.
Key highlights: Burke led ALPS revenue growth from $15 million to $225 million (2005–2019; ~19.79% CAGR), negotiated ALPS sales to Lovell Minnick Partners (2005) and DST Systems (2011), and received the 2016 NOVA Award. He also serves on multiple mutual fund boards and is noted as one of Glucose Health’s largest shareholders.
Glucose Health (OTC: GLUC) ha nominato Edmund “Ned” Burke al suo Consiglio di Amministrazione con effetto dal 27 ottobre 2025. Burke è un dirigente finanziario veterano con oltre 40 anni di esperienza in società tra cui Pioneer Funds e Fidelity, e ha ricoperto la carica di CEO di ALPS Holdings fino al suo pensionamento a giugno 2019.
Punti chiave: Burke ha guidato la crescita dei ricavi di ALPS da 15 milioni a 225 milioni di dollari (2005–2019; CAGR ~19,79%), ha negoziato le vendite di ALPS a Lovell Minnick Partners (2005) e DST Systems (2011), e ha ricevuto l NOVA Award nel 2016. Serve anche in diversi consigli di fondi comuni ed è noto come uno dei maggiori azionisti di Glucose Health.
Glucose Health (OTC: GLUC) designó a Edmund “Ned” Burke a su Junta Directiva, con efecto a partir del 27 de octubre de 2025. Burke es un ejecutivo financiero veterano con más de 40 años en firmas como Pioneer Funds y Fidelity, y se desempeñó como CEO de ALPS Holdings hasta su retiro en junio de 2019.
Aspectos clave: Burke dirigió el crecimiento de ingresos de ALPS de 15 millones a 225 millones de dólares (2005–2019; CAGR ≈ 19,79%), negoció las ventas de ALPS a Lovell Minnick Partners (2005) y DST Systems (2011), y recibió el NOVA Award en 2016. También forma parte de varias juntas de fondos mutuos y es reconocido como uno de los mayores accionistas de Glucose Health.
글루코스 헬스(OTC: GLUC)는 2025년 10월 27일부로 Edmund “Ned” Burke를 이사회 이사로 선임했습니다. Burke는 Pioneer Funds와 Fidelity를 포함한 여러 회사에서 40년이 넘는 경력을 가진 베테랑 금융 경영진이며, 2019년 6월 은퇴할 때까지 ALPS Holdings의 CEO로 재임했습니다.
핵심 하이라이트: Burke는 ALPS의 매출을 1,500만 달러에서 2억 2,500만 달러로 성장시키는 데 이끌었고(2005–2019; 약 19.79% CAGR), ALPS의 매출을 Lovell Minnick Partners(2005) 및 DST Systems(2011)에 매각하는 것을 협상했으며, 2016 NOVA Award를 수상했습니다. 또한 다수의 뮤추얼 펀드 이사회에 재직 중이며 Glucose Health의 최대 주주 중 한 명으로 알려져 있습니다.
Glucose Health (OTC: GLUC) a nommé Edmund “Ned” Burke au conseil d’administration, à compter du 27 octobre 2025. Burke est un dirigeant financier chevronné avec 40 années d’expérience dans des sociétés telles que Pioneer Funds et Fidelity, et il a été CEO d’ALPS Holdings jusqu’à sa retraite en juin 2019.
Points clés : Burke a dirigé la croissance des revenus d’ALPS de 15 millions à 225 millions de dollars (2005–2019; CAGR d’environ 19,79 %), a négocié les ventes d’ALPS à Lovell Minnick Partners (2005) et DST Systems (2011), et a reçu le NOVA Award en 2016. Il siège également à plusieurs conseils de fonds mutuels et est reconnu comme l’un des plus grands actionnaires de Glucose Health.
Glucose Health (OTC: GLUC) hat Edmund “Ned” Burke zum Vorstand berufen, gültig ab dem 27. Oktober 2025. Burke ist ein erfahrener Finanzmanager mit über 40 Jahren Erfahrung bei Unternehmen wie Pioneer Funds und Fidelity und fungierte bis zu seinem Ruhestand im Juni 2019 als CEO von ALPS Holdings.
Wichtige Highlights: Burke führte das Umsatzwachstum von ALPS von 15 Millionen auf 225 Millionen Dollar (2005–2019; ~19,79% CAGR) an, verhandelten den Verkauf von ALPS an Lovell Minnick Partners (2005) und DST Systems (2011), und erhielt den NOVA Award im Jahr 2016. Er ist außerdem Mitglied mehrerer Vorstände von Investmentfonds und gilt als einer der größten Anteilseigner von Glucose Health.
Glucose Health (OTC: GLUC) عيّنت إدمندورغ "Ned" Burke في مجلس إدارتها اعتباراً من 27 أكتوبر 2025. Burke هو مدير مالي مخضرم لديه أكثر من 40 عاماً من الخبرة في شركات مثل Pioneer Funds وFidelity، وشغل منصب الرئيس التنفيذي لـ ALPS Holdings حتى تقاعده في يونيو 2019.
اللمحات الرئيسية: قاد Burke نمو إيرادات ALPS من 15 مليون دولار إلى 225 مليون دولار (2005–2019؛ معدل نمو سنوي مركب ~19.79%)، تفاوض على بيع ALPS إلى Lovell Minnick Partners (2005) وDST Systems (2011)، وتلقى جائزة NOVA في 2016. كما يخدم في عدة مجالس صناديق استثمار مشتركة وهو معروف كأحد كبار المساهمين في Glucose Health.
Glucose Health (OTC: GLUC) 已任命 Edmund “Ned” Burke 为其董事会成员，生效日期为2025年10月27日。Burke 是一位资深金融高管，拥有40多年在 Pioneer Funds 和 Fidelity 等公司的经历，曾任 ALPS Holdings 的首席执行官，直至2019年6月退休。
主要亮点： Burke 将 ALPS 的收入从1500万美元提升至2.25亿美元（2005–2019；约19.79%的复合年增长率），并促成 ALPS 出售给 Lovell Minnick Partners（2005）和 DST Systems（2011）的交易；他还在2016年获得 NOVA 奖。他还在多家共同基金董事会任职，并被认为是 Glucose Health 的最大股东之一。
- ALPS revenue growth from $15M to $225M (2005–2019)
- 19.79% CAGR reported for ALPS revenue over ~15 years
- Board alignment as one of Glucose Health’s largest shareholders
- Retired from CEO role in June 2019 (no recent CEO operational role)
BENTONVILLE, Ark., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) is pleased to announce the appointment of Edmund (Ned) Burke, a highly accomplished financial services executive, to its Board of Directors. With more than four decades of experience at prominent investment firms, including Pioneer Funds and Fidelity Investments, Mr. Burke brings exceptional financial acumen and strategic insight to the company’s leadership team.
Mr. Burke most recently served as Chief Executive Officer of ALPS Holdings, Inc., where he played a pivotal role in the successful distribution and administration of closed-end funds, open-end funds, and exchange-traded funds (ETFs). Under his direction, ALPS expanded its services to include critical back-office solutions for many of the nation’s top money management firms. During his tenure, Mr. Burke established and managed key relationships with notable organizations, including Select Sector SPDR Exchange Traded Funds, GE Investment Management, and Clough closed-end funds.
His outstanding contributions to the financial services industry were recognized in 2016 when he received the NOVA Award from the National Investment Company Service Association, honoring his leadership and innovation in the securities sector.
As CEO, Mr. Burke oversaw impressive growth at ALPS, expanding the firm’s revenue from
Mr. Burke’s extensive experience in building and scaling financial organizations will be invaluable as Glucose Health, Inc., continues to expand operations and enhance shareholder value. In addition to his new Board role at Glucose Health, Mr. Burke serves on the mutual fund boards of several prominent money management firms, including Financial Investors Trust, ALPS ETF Trust, Clough Funds, and Liberty All-Star Trust.
Commenting on the appointment, Mark Schaftlein, CEO of Glucose Health, stated:
“Ned is an outstanding addition to our Board of Directors. His business experience and proven success in building high-performing organizations will be instrumental as we continue to advance Glucose Health’s growth strategy. As one of our largest shareholders, Ned’s interests are perfectly aligned with those of our broader shareholder base, and I look forward to working closely with him to achieve our long-term objectives.”
Mr. Burke earned a Bachelor of Arts degree in Economics from the University of New Hampshire.
Contact: Investor Relations info@glucosehealthinc.com www.glucodown.com www.fiberup.com OTC: GLUC
FAQ
Who is Edmund “Ned” Burke and why did Glucose Health (GLUC) appoint him on Oct 27, 2025?
What growth track record does Ned Burke bring to Glucose Health (GLUC)?
Does Ned Burke have transaction experience relevant to GLUC shareholders?
Is Ned Burke actively serving in other industry roles while joining GLUC’s board?
Will Ned Burke’s appointment affect shareholder alignment for GLUC (OTC: GLUC)?
